On October 24, 2024, IRBM’s CEO Matteo Liguori represented the organization at the G7 Ministerial Meeting on Development. This high-level event gathered Development Ministers from G7 countries, partner nations, international organizations, and business leaders to advance public health through global cooperation. IRBM’s participation highlights our role as a key contributor in drug discovery, recognized by international institutions for addressing critical health challenges.
Public-Private Partnerships: Driving Global Health Forward
Aligning Efforts with Gavi and Other Global Health Leaders
IRBM’s involvement also aligns with the mission of organizations like Gavi, the Vaccine Alliance. Led by José Manuel Barroso, Gavi vaccinates over half of the world’s children against life-threatening diseases, pushing for a more equitable healthcare landscape. At IRBM, we share this vision—collaborating to make life-saving vaccines more accessible globally and contributing to health equity.
During the G7 meeting, IRBM engaged with stakeholders to explore strategies for strengthening healthcare resilience, advancing drug and vaccine development, and improving access to preventive care. Our participation underscored the importance of leveraging private sector expertise to support public health objectives and ensure rapid responses to future health crises.
IRBM’s Ongoing Commitment to Global Health
If your organization is committed to advancing drug and vaccine innovation, let’s discuss how our expertise can help. At IRBM, we provide comprehensive support during the discovery phase, delivering cutting-edge solutions with a focus on scientific progress and global health impact. Additionally, our sister company, Advaxia Biologics, offers fully integrated services for adenovirus vaccines, covering everything from development to manufacturing for pre-clinical and clinical supply.